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Normally a benign commensal colonizer of mucosal surfa-
ces such as the gastrointestinal tract, Candida albicans is
also one of the most common fungal pathogens of humans,
responsible for both superﬁcial as well as life-threatening
invasive infections. Arguably the commonest type of infec-
tion caused by C. albicans is vulvovaginal candidiasis
(VVC), as it affects 75% of women of childbearing age.1
And unlike many other manifestations of candidiasis, which
are associated with particular immune deﬁciencies, VVC
frequently occurs in otherwise healthy women.
Symptomatic VVC can be associated with the use of
(antibacterial) antibiotics. It is thought that elimination
of the protective bacterial vaginal ﬂora allows Candida
overgrowth and symptomatic disease. Indeed, for dis-
eases of normally non-sterile sites such as mucosae, the
balance of the microbial community (the microbiota)
has a very important impact on the outcome of a particu-
lar host-pathogen interaction, and the presence of com-
mensal organisms can elicit “colonization resistance”
against potential pathogens.2,3 In this context, the princi-
ple of preventing or treating microbial infections with
other microbes, has a long history, and a number of stud-
ies suggest that such approaches can be clinically beneﬁ-
cial. For example, the commensal species Clostridium
scindens can protect mice from Clostridium difﬁcile
infections.4 Because Lactobacilli species are the dominant
microbiota of the healthy vagina, imbalances in these
species are implicated in VVC and there is some evi-
dence for protective effects of Lactobacillus probiotic
administration.5
In this issue of Virulence, Pericolini and colleagues
looked at the effect of Saccharomyces cerevisiae yeast
administration on the course of infection in a murine
model of VVC. They found that postinfection vaginal
administration of live or inactivated S. cerevisiae
enhanced clearance of infecting C. albicans cells.6 The
authors used in vivo imaging of mice infected with a C.
albicans strain expressing the luciferase bioluminescent
protein. Using this technique, it is possible to noninva-
sively track, over time, the progression, and resolution of
VVC in living mice. Intriguingly, they found that a single
administration of live S. cerevisiae cells elicited Candida
clearance at levels comparable to treatment with the
commonly used antifungal drug, ﬂuconazole. Of note,
even inactivated yeast cells elicited fungal clearance, but
this was not as sustained as was observed for viable Sac-
charomyces cells. This suggested that S. cerevisiae cells
may be used therapeutically for the treatment of VVC;
but how do yeast cells help to resolve VVC?
C. albicans infections of mucosal surfaces rely on a com-
plex number of interlinked fungal pathogenicity mecha-
nisms and virulence factors centered around the fulcrum of
hyphal morphogenesis.7 Primarily, the pathogen must
adhere robustly to its host to initiate colonization, and
hypha formation strengthens adhesion potential substan-
tially due to the expression of hypha co-expressed genes
which encode the adhesin proteins Als3 and Hwp1, among
others.8 C. albicans hyphae are also essential for epithelial
invasion, not only due to the penetrative nature of the
extending ﬁlament, but because the hypha coexpressed
adhesin Als3 also functions as an invasin, triggering fungal
uptake by epithelial cells.9 Although this process has not yet
been tested for C. albicans-vaginal cell interactions, induced
endocytosis via Als3-cadherin interactions is an established
mechanism of fungal invasion of both oral epithelial and
endothelia cells.10
C. albicans also produces an array of factors which can
damage host tissue at mucosal surfaces, including secreted
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hydrolases such as aspartyl proteases, lipases and phospholi-
pases and a cytolytic toxin called Candidalysin.11,12 In com-
bination, the activities of hypha formation, adhesion,
invasion, as well as hydrolase and cytolysin secretion can
damage epithelial cells and trigger epithelial immunity.13
However, in the context of vaginal candidiasis, proinﬂam-
matory responses seem to do more harm than good, as
symptomatic disease appears to be the result of an aggres-
sive, and nonprotective, inﬂux of neutrophils.14
Pericolini et al. therefore questioned whether the ther-
apeutic effect of Saccharomyces cells observed in their
animal infection model of VVC was due to interference
with or modulation of speciﬁc C. albicans pathogenicity
factors. Using tissue culture models of C. albicans-epi-
thelial interactions, they found that pre-treating the epi-
thelia with either live or inactivated yeast cells inhibited
C. albicans adhesion to the vaginal epithelial cells. This
inhibition of C. albicans adhesion by both living and
inactivated yeast cells was likely due to physical competi-
tion and aggregation between the fungi.
The authors next investigated the effect of Saccharomy-
ces on C. albicans morphogenesis. Here, they found that
living, but not inactivated yeast cells strongly repressed C.
albicans hypha formation and even the cell free superna-
tant of S. cerevisiae cultures had an inhibitory effect. This
is an important observation because the expression of
multiple C. albicans pathogenicity- and virulence- factors
is intimately linked to hyphal morphogenesis. That is,
either chemical- or genetic- inhibition of the yeast to
hypha transition also blocks C. albicans adhesion to, inva-
sion and damage of mammalian epithelial cells.8,15
Similarly, viable Saccharomyces cells were also able to
block the expression of SAP2 and SAP6 by C. albicans
both in vitro and in the mouse model of VVC. These two
genes encode secreted aspartyl proteases which have long
been implicated in C. albicans virulence.16 Interestingly,
Saps can also inﬂuence the inﬂammatory pathogenesis of
VVC: administration of recombinant Sap2 to the vaginal
cavity results in pronounced IL1b production and neutro-
phil inﬂux in mouse models, even in the absence of infect-
ing Candida cells.17 As such neutrophil inﬂux appears to
be nonprotective in the context of VVC14, and may actu-
ally drive the symptomatic pathogenesis of this disease,
Saccharomyces-treatment might help resolve symptoms,
not only by enhancing C. albicans clearance, but also by
dampening inﬂammatory responses. In the future, it will
be interesting to examine the impact of Saccharomyces
administration on local inﬂammatory responses and neu-
trophil inﬁltration to the site of infection.
Therefore, viable S. cerevisiae cells not only physically
perturb C. albicans colonization of epithelia, but also
directly inhibit the elaboration of several key pathogenic-
ity factors. This study underscores the complex
interactions which can occur between microbial cells
within a mammalian host and the impact these multi-
species interactions have on the outcome of an infection.
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